Candriam SCA’s Calithera Biosciences, Inc CALA Stock Holding History

Candriam SCA’s Portfolio CALA Stock Details CALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,000	Closed	-$699K	–	826
2019 Q2	$699K	Hold	9,000	–	–	0.01%	706
2019 Q1	$1.21M	Hold	9,000	–	–	0.02%	590
2018 Q4	$722K	Hold	9,000	–	–	0.01%	639
2018 Q3	$945K	Hold	9,000	–	–	0.01%	630
2018 Q2	$900K	Hold	9,000	–	–	0.01%	630
2018 Q1	$1.13M	Buy	9,000 +3,000	+50%	+$468K	0.02%	574
2017 Q4	$1M	Sell	6,000 -5,000	-45%	-$1.28M	0.02%	586
2017 Q3	$3.46M	Sell	11,000 -2,405	-18%	-$759K	0.06%	345
2017 Q2	$3.98M	Sell	13,405 -2,855	-18%	-$764K	0.07%	312
2017 Q1	$3.76M	Buy	16,260 +6,750	+71%	+$1.17M	0.07%	313
2016 Q4	$618K	Hold	9,510	–	–	0.01%	588
2016 Q3	$618K	Hold	9,510	–	–	0.01%	567
2016 Q2	$706K	Hold	9,510	–	–	0.02%	501
2016 Q1	$1.07M	Sell	9,510 -240	-2%	-$27.2K	0.03%	418
2015 Q4	$1.49M	Hold	9,750	–	–	0.04%	338
2015 Q3	$1.06M	Sell	9,750 -1,750	-15%	-$227K	0.03%	429
2015 Q2	$1.64M	Buy	11,500 +2,000	+21%	+$464K	0.03%	383
2015 Q1	$3.12M	Buy	+9,500	New	+$3.38M	0.06%	331

Other funds holding CALA

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Candriam SCA's CALA Position: Q3 2019 in Review

Candriam SCA sold out of Calithera Biosciences, Inc (CALA) in Q3 2019, closing a stake of 9,000 shares — an estimated $699K sold.

Candriam SCA first reported a position in CALA in Q1 2015 and held it in 18 quarters. The position peaked at $3.98M in Q2 2017. 85 funds tracked by Wall St. Rank hold CALA as of Q3 2019.

Candriam SCA reported no remaining Calithera Biosciences, Inc position as of Q3 2019 after selling out during the quarter.
Candriam SCA sold 9,000 Calithera Biosciences, Inc shares in Q3 2019, an estimated $699K.
Candriam SCA first reported a position in Calithera Biosciences, Inc in Q1 2015 and held it in 18 quarters.
Candriam SCA's Calithera Biosciences, Inc position peaked at $3.98M in Q2 2017.
85 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2019.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.